Pantoprazole-Induced Thrombocytopenia in a Patient with Upper Gastrointestinal Bleeding: A Case Report

Maryam

Department of Pharmacy Practice, Deccan School of Pharmacy, Nampally, Hyderabad, Telangana State, India and Department of Pharmacy Practice, Yenepoya Pharmacy College & Research Centre, Yenepoya (Deemed to be University), Ayush campus, Deralakatte, Mangalore, Karnataka, India.

Treesa P. Varghese *

Department of Pharmacy Practice, Yenepoya Pharmacy College & Research Centre, Yenepoya (Deemed to be University), Ayush campus, Deralakatte, Mangalore, Karnataka, India.

Syeda Neha Fatima

Department of Pharmacy Practice, Deccan School of Pharmacy, Nampally, Hyderabad, Telangana State, India.

Iqra Jahan

Department of Pharmacy Practice, Deccan School of Pharmacy, Nampally, Hyderabad, Telangana State, India.

*Author to whom correspondence should be addressed.


Abstract

Although it seems relatively rare, pantoprazole-induced thrombocytopenia is a potentially serious side effect[6]. Proton pump inhibitors (PPIs), which have the potential to stabilize blood clot formation, are frequently used in the treatment of upper gastrointestinal bleeding (UGIBs)[7]. Helicobacter pylori infection, stomach ulcers, erosive esophagitis, and stress ulcer prophylaxis in high-risk critically ill individuals are the indications for PPI therapy. In intensive care units (ICUs), stress ulcer prophylaxis with acid-suppressing therapy is frequently prescribed. PPIs are a class of medications that are routinely used in intensive care units (ICU) to treat and prevent stress ulcers (stress-related mucosal disease). The mainstay of treatment for peptic ulcer bleeding includes PPIs, with consensus recommendations currently prescribing high-dose intravenous (IV) PPI therapy (IV bolus followed by continuous therapy).2 PPIs have been demonstrated to lessen symptoms of bleeding at index endoscopy and to lessen rebleeding following endoscopic hemostasis. Although PPIs are well-tolerated and frequently given to patients with acute UGIBs, serious side effects could happen. Patients who used PPIs for a brief period of time experienced a variety of moderate systemic symptoms. When taking PPIs for less than two weeks, serious adverse effects typically start off moderate. However, as treatment time goes on, side effects have been found to become more frequent and severe.  Patients with UGIBs may experience significant hemodynamic instability and rebleeding risks due to thrombocytopenia. Here, we present a case of thrombocytopenia that developed after pantoprazole was introduced. After the drug was discontinued, the thrombocytopenia was recovered. According to the Naranjo probability scale causality assessment, the relationship between thrombocytopenia and pantoprazole is found to be probable. We emphasize this case to raise awareness about drug-induced thrombocytopenia.

Keywords: Proton pump inhibitors, pantoprazole, rare adverse drug reaction, thrombocytopenia, pantoprazole-induced thrombocytopenia


How to Cite

Maryam, Treesa P. Varghese, Syeda Neha Fatima, and Iqra Jahan. 2024. “Pantoprazole-Induced Thrombocytopenia in a Patient With Upper Gastrointestinal Bleeding: A Case Report”. Asian Journal of Research and Reports in Gastroenterology 7 (1):30-33. https://journalajrrga.com/index.php/AJRRGA/article/view/126.

Downloads

Download data is not yet available.

References

Jaynes M, Kumar AB. The risks of long-term use of proton pump inhibitors: A critical review. Ther Adv Drug Saf. 2018 Nov 19;10:2042098618809927.

van Rensburg CJ, Cheer S. Pantoprazole for the treatment of peptic ulcer bleeding and prevention of rebleeding. Clin Med Insights Gastroenterol. 2012 Sep 17; 5:51-60.

Phan AT, Tseng AW, Choudhery MW, Makar JB, Nguyen C, Farmand F. Pantoprazole-Associated Thrombocytopenia: A Literature Review and Case Report. Cureus. 2022 Feb 17;14(2):e22326.

Subhajit Mukherjee,Tanima Jana and Jen-Jung Pan, Adverse Effects of Proton Pump Inhibitors on Platelet Count: A Case Report and Review of the Literature, Case Reports in Gastrointestinal Medicine. 2018;2090-6528

Naranjo CA, Busto U, Sellers EM et al. A methodd for estimating the probability of adverse drug reactions. Clin Pharmacol Ther,1981;30:239-4

Widyati, Latifah N, Ramadhani M. Pantoprazole-induced Thrombocytopenia: Unresponsive to Corticosteroid and Thrombocyte Concentrate Transfusion. Journal of Pharmacy Practice. 2023;36(3): 711-715.

Yu Z, Hu J, Hu Y. Neutropenia and Thrombocytopenia Induced by Proton Pump Inhibitors: A Case Report. Drug Saf - Case Rep. 2018;5:28.

Watson TD, Stark JE, Vesta KS. Pantoprazole-induced thrombocytopenia. The Annals of Pharmacotherapy. 2006; 40(4):758–761.

Randi Katz, Jason Bratcher, Efrat Dotan, Carrie Wasserman, Michelene Liebman, Sivakumar Reddy, Amy Michael, Aliasad Arastu, Georgia Panagopoulos, Colette Spaccavento; The Prevalence of Pantoprazole Associated Thrombocytopenia in a Community Hospital - A Retrospective Study. Blood. 2005;106(11):3980.